Pancreatic Cancer Research

ResearcherUniversity of Yamanashi HospitalActive in the last 2 years

Hiroshi Onishi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3512-1166; OpenAlex author ID A5081837886. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Enhancing pancreatic cancer staging with large language models: the role of retrieval-augmented generation. Co-author DOI 10.1007/s12194-026-01026-0↗
  2. Correction to: Transarterial fiducial marker implantation for CyberKnife radiotherapy to treat pancreatic cancer: an experience with 14 cases. Last author DOI 10.1007/s11604-023-01405-2↗
  3. Optimal target b-value on computed diffusion-weighted magnetic resonance imaging for visualization of pancreatic ductal adenocarcinoma and focal autoimmune pan… Last author DOI 10.1007/s00261-020-02695-0↗
  4. Transarterial fiducial marker implantation for CyberKnife radiotherapy to treat pancreatic cancer: an experience with 14 cases. Last author DOI 10.1007/s11604-020-01040-1↗
  5. Diffusion-weighted image improves detectability of magnetic resonance cholangiopancreatography for pancreatic ductal adenocarcinoma concomitant with intraducta… Co-author DOI 10.1097/md.0000000000018039↗
  6. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer. Last author DOI 10.1007/s00261-018-1647-4↗
  7. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival. Co-author DOI 10.1016/j.ijrobp.2011.07.013↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shintaro Ichikawa · 3 shared papers, 2018–2021 · strength 0.36
  2. Akira Imaizumi · 2 shared papers, 2021–2023 · strength 0.33
  3. Kazunori Nakamoto · 1 shared paper, 2026 · strength 0.27
  4. Atsushi Komaba · 1 shared paper, 2026 · strength 0.27
  5. Hisashi Johno · 1 shared paper, 2026 · strength 0.27
  6. Yoshie Omiya · 1 shared paper, 2018 · strength 0.10
  7. Satoshi Kawakami · 1 shared paper, 2019 · strength 0.07
  8. Shinichi Takano · 1 shared paper, 2019 · strength 0.07
  9. Makoto Kadokura · 1 shared paper, 2019 · strength 0.07
  10. Hiromichi Kawaida · 1 shared paper, 2019 · strength 0.07
  11. Nobuyuki Enomoto · 1 shared paper, 2019 · strength 0.07
  12. Kazuhiko Ogawa · 1 shared paper, 2012 · strength 0.03
  13. Keiko Shibuya · 1 shared paper, 2012 · strength 0.03
  14. Katsuyuki Karasawa · 1 shared paper, 2012 · strength 0.03
  15. Yasumasa Nishimura Md · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.